By Metro US
Posted on
KUALA LUMPUR (Reuters) – Malaysia’s health ministry said on Tuesday it has given conditional approval for the use of the single-dose antibody cocktail Ronapreve, developed by Regeneron and Roche, to treat COVID-19.
It has also approved a request from Merck & Co for a clinical trial import license for its COVID-19 pill Molnupiravir, to be used as part of studies being conducted in Malaysia, the ministry said in a statement.
(Reporting by Rozanna Latiff; Editing by Ed Davies)
Haliburton breaks tie with 3-point play, Pacers beats Bucks 121-118 in OT to take 2-1 series lead
No. 1 NFL draft pick Caleb Williams realizes all eyes are on him and he’s embracing the attention
The long wait for the 1st running back to be drafted ends with Jonathan Brooks going 46th
Caitlin Clark revs up Pacers fans with pregame playoff appearance in IndyCar replica
NFL to allow players to wear protective soft-shell helmet covers during games
Midwest tornadoes cause severe damage in Omaha suburbs
Biden officials indefinitely postpone ban on menthol cigarettes amid election-year pushback
A ban in Kansas on gender-affirming care also would bar advocacy for kids’ social transitions
South Dakota governor, a potential Trump running mate, writes in new book about killing her dog
140,000 people did their taxes with the free IRS direct file pilot. But program’s future is unclear
A ban in Kansas on gender-affirming care also would bar advocacy for kids’ social transitions
What to know about Bell’s palsy, the facial paralysis affecting Joel Embiid
South Korean police raid office of incoming head of doctors’ group over protracted strikes
USDA tells producers to reduce salmonella in certain frozen chicken products
